title: Off-label use of Sorafenib in patients with advanced thyroid carcinoma: Retrospective analysis of five cases.
abstract: We present results obtained in five patients with advanced thyroid cancer, derived from the follicular epithelium, treated with Sorafenib used off-label. The median age at the time Sorafenib was started was 61 years. Only one patient tolerated the standard dose of 400 mg twice daily. The most severe adverse events were.
authors.affiliation: Endocrinology Service, Portuguese Institute of Oncology Francisco Gentil EPE; NOVA Medical School/NOVA Medical School, Lisbon, Portugal.
authors.forename: Maria João
authors.initials: MJ
authors.lastname: Bugalho
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D056687:Off-Label Use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011878:Radiotherapy; D000077157:Sorafenib; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib